Similar articles

• Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.

  Wasmuth JC, Herhaus C, Römer K, Salzberger B, Kaiser R, Schliefer K, Voigt E, Rockstroh JK. Wasmuth JC, et al. AIDS. 2002 May 3;16(7):1077-8. doi: 10.1097/00002030-200205030-00018. AIDS. 2002. PMID: 11953478 No abstract available.
• Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.

  Ruane P, Lang J, DeJesus E, Berger DS, Dretler R, Rodriguez A, Ward DJ, Lim ML, Liao Q, Reddy S, Clair MS, Vila T, Shaefer MS. Ruane P, et al. HIV Clin Trials. 2006 Sep-Oct;7(5):229-36. doi: 10.1310/hct0705-229. HIV Clin Trials. 2006. PMID: 17162316 Clinical Trial.
• Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.

  Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE; COL30336 Study Team. Ruane PJ, et al. HIV Clin Trials. 2003 Jul-Aug;4(4):231-43. doi: 10.1310/MM9W-BAU0-BT6Q-401B. HIV Clin Trials. 2003. PMID: 12916008 Clinical Trial.
• A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.

  Wolbach J, Capoccia K. Wolbach J, et al. Nurse Pract. 1999 Jun;24(6):81-2, 87-90, 92. Nurse Pract. 1999. PMID: 10431297 Review. No abstract available.
• Dose-ranging studies.

  Manion D. Manion D. Int J Clin Pract Suppl. 1999 Jun;103:8-9. Int J Clin Pract Suppl. 1999. PMID: 10622036 Review.